News & Events

Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020  

HALLE (SAALE) / MUNICH, Germany, 20 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, […]

Vivoryon Receives IND Approval for Varoglutamstat‘s (PQ912) Phase 2 Study in Alzheimer’s Disease

HALLE (SAALE) / Munich, Germany, 04 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the U.S. Food and Drug Administration (FDA) […]

Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer’s Disease Study with Varoglutamstat (PQ912)

HALLE (SAALE) / Munich, Germany, 15 July 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the first patient has been enrolled in […]

Vivoryon Therapeutics Provides Update on US and EU Alzheimer’s Clinical Trial Program with PQ912

Vivoryon and the Alzheimer’s Disease Cooperative Study (ADCS) have developed a new trial design for Phase 2a Alzheimer’s trial in the US; as a stage gate […]

Vivoryon Therapeutics AG Reports First Quarter 2020

HALLE (SAALE) / MUNICH, Germany, 14 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today its first quarter business update for the period […]

Vivoryon Therapeutics AG Postpones Annual General Meeting

HALLE (SAALE) / Munich, Germany, 12 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which […]

Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020  

HALLE (SAALE) / Munich, Germany, 7 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish […]

Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys

MorphoSys will not execute the option deal to license Vivoryon’s small molecule QPCTL inhibitors for oncology   Vivoryon will continue to evaluate QPCTL inhibitors in oncology […]

Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease

HALLE (SAALE) / MUNICH and LEIPZIG, Germany, 16 April 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that the Company has entered […]